WO2002034268A1 - Preparation a liberation prolongee contenant comme principe actif du trihydrochlorure de 5-acetyl-4,6-dimethyl-2-(2-(4-(2-methoxyphenyl)piperazinyl)ethylamino)pyrimidine - Google Patents
Preparation a liberation prolongee contenant comme principe actif du trihydrochlorure de 5-acetyl-4,6-dimethyl-2-(2-(4-(2-methoxyphenyl)piperazinyl)ethylamino)pyrimidine Download PDFInfo
- Publication number
- WO2002034268A1 WO2002034268A1 PCT/JP2001/009241 JP0109241W WO0234268A1 WO 2002034268 A1 WO2002034268 A1 WO 2002034268A1 JP 0109241 W JP0109241 W JP 0109241W WO 0234268 A1 WO0234268 A1 WO 0234268A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- release
- sustained
- acetyl
- piperazinyl
- methyl methacrylate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
Definitions
- the present invention relates to 5-acetyl-4,6-dimethyl-2- [2- [4- (2-methyl
- 3HCI 5-H-acetyl-4,61-dimethyl-21- [2- [4- (2-methoxyphenyl) piperazinyl] ethylamino] pyrimidine 'trihydrochloride
- 3HCI has an ⁇ -blocker effect. It is useful as a therapeutic agent for dysuria (JP-A-62-51672, JP-A-3-90027 (USP 5,075,308)). Although this compound is stable, it has properties that both absorption and metabolism are fast, so that effective blood levels cannot be maintained for a long time.
- the blood concentration pattern of a normal tablet tablette containing 3 mg of the present compound prepared in Comparative Example 1 described later
- the present inventors have studied the preparation of a sustained-release preparation of the present compound.
- sustained-release preparation When preparing a sustained-release preparation, coating is usually performed around the granules or tablets with a sustained-release film.
- the present inventors also conducted various studies on this technique, and found that ethyl cellulose, ethyl acrylate, methyl methacrylate, methacrylated trimethylammonium muethyl copolymer (Eudragit RS 30 D, registered trademark, It was confirmed that sustained-release preparations using (Pharma Co., Ltd.) as a controlled release membrane could release the drug continuously for over 12 hours. However, in all cases, the elution rate was greatly affected by the pH, and the release pattern was not constant, and it was colored over time and lacked stability.
- the present inventors considered that the release pattern of the above-mentioned preparations was not stable and unstable over time, possibly because the compound was a hydrochloride.
- the present invention relates to the following sustained-release preparations 1 to 5.
- the water-insoluble polymer having no hydrophilic group is composed of ethyl acrylate and Slow-release of 5-acetyl-4,6-dimethyl 2- [2- [4- (2-methoxyphenyl) piperazinyl] ethylamino] pyrimidine trihydrochloride as described in 1 above, which is a copolymer of methyl acrylate Formulation.
- the sustained-release preparation of the present invention comprises drug particles and a release controlling film.
- Drug particles consist of the present compound, excipients, fluidizers, binders, etc., and are prepared by crushing, mixing and granulating.
- excipient examples include corn starch and the like.
- fluidizing agent examples include light anhydrous silicic acid.
- binder examples include hydroxypropyl cellulose and the like.
- the core material may or may not be used, but the use of the core material is more advantageous in terms of sphericity and stability of the release pattern.
- sucrose or cellulose can be used as the core material.
- the compounding ratio of the present compound and excipients in the drug particles is, for example, about 100 g of the present compound, about 300 to 700 g of excipient, and about 3 to 30 g of a fluidizing agent.
- the core material is used up to about 2500 g.
- the controlled-release film used in the sustained-release preparation of the present invention is not particularly limited as long as it is a film made of a pharmaceutically acceptable water-insoluble polymer having no hydrophilic group.
- the hydrophilic group refers to a group that has an affinity for water, such as a hydroxyl group, an amino group, and a hydroxyl group. It may be ionic or non-ionic.
- Preferred materials used as the controlled release film in the present invention include a copolymer of ethyl acrylate and methyl methacrylate.
- a more preferred release controlling film material is a copolymer in which the ratio of ethyl acrylate to methyl methacrylate is 1 to 4 ethyl acrylates per 1 methyl methacrylate. A more desirable ratio is 1.5 to 3.5 of ethyl acrylate to 1 of methyl methacrylate.
- an ethyl acrylate-methyl methacrylate copolymer emulsion (Eudragit NE 30D (registered trademark, manufactured by Laem Pharma)) is listed. I can do it.
- Eudragit NE 30D is an emulsion of a copolymer obtained in an aqueous solution of ethyl acrylate and methyl methacrylate in a polyoxyethylene noel phenyl ether (100E. ⁇ .) Solution.
- the dried product contains 7.0 to 10.0% of methoxyl groups and 21.0 to 33.0% of ethoxyl groups.
- the sustained-release preparation of the present invention can be produced, for example, by the following method.
- a water-insoluble polymer having no hydrophilic group, an anti-adhesion agent (eg, talc, etc.) and a solvent (eg, water, etc.) are mixed, and the obtained emulsion is mixed with a fluidizing agent (eg, light anhydrous 4. Coat the dry particles of 4 with an acid.
- a fluidizing agent eg, light anhydrous 4.
- Curing by holding the controlled release film on the particles at a temperature of 50-100 ° C., preferably 60-80 ° C., for 30 minutes to 12 hours, preferably 1 to 8 hours. Is performed.
- the controlled release membrane is preferably coated in an amount to provide about 10 to 14% by weight of the cured drug particles.
- FIG. 9 shows a preferred embodiment of the preparation particles of the present invention, which comprises a granulation core material (1) and a drug layer (2) of the present compound coated with a controlled release film (3) of the present invention.
- FIG. 4 shows a partially cutaway perspective view.
- the granules are granulated by the above method to give granules having an average particle size of 0.1 mm to several mm, preferably about lmm. This granule can be used as it is as a granule or filled into a capsule to form a final product.
- FIG. 1 is a graph showing the pattern of blood drug concentration when a normal tablet of the present compound was administered to humans.
- FIG. 2 is a graph showing blood drug concentration patterns when a sustained release preparation of the present invention was administered to humans.
- FIG. 3 is a graph showing the release patterns of the preparation of the present invention at various pHs.
- FIG. 4 is a graph showing the release pattern of the preparation of the present invention after the accelerated test.
- FIG. 5 is a graph showing the release pattern of a normal tablet of the present compound.
- FIG. 6 is a graph showing the release patterns at various pHs of a sustained-release preparation of the present compound using an ethylcellulose membrane.
- FIG. 7 is a graph showing the release pattern of the sustained-release preparation of the present compound using an ethylcellulose membrane after an accelerated test.
- FIG. 8 is a graph showing the release patterns at various pHs of a sustained-release preparation by Eudragit RS30D film of the present compound.
- FIG. 9 is a partially cutaway perspective view of a preferred embodiment of the sustained release preparation of the present invention.
- Example 1 Production of sustained-release preparation of the present invention
- This compound (the drug substance; 30 g), corn starch (187.5 g) and light anhydrous silicic acid (lg) were mixed.
- Crystalline cellulose particles 700 g, particle size 0.5-0.7 mm
- the granules were dried using a fluid bed dryer and classified.
- the obtained drug particles (average particle size: 600 to 700 Aim, 400 g) were added to talc (24 g) and an aqueous suspension of Eudragit NE 30D (registered trademark; Rohm Pharma Co., 80 g, solid content 24 g).
- Example 2 Mass production of the sustained-release preparation of the present invention
- Example 1 the amounts of the raw materials were as follows: the present compound (the drug substance; 1.6 kg), corn starch (9.8 kg), light anhydrous silicic acid (60 g), crystalline cellulose particles (37 kg, particle size 0.5 to 0.7 mg), The same procedure as in Example 1 (method of producing drug particles) was performed in place of hydroxypropyl cellulose (1.705 kg) and an ethanol solution (18.3 kg) to obtain drug particles of about 50 kg.
- Example 1 Method of manufacturing a drug control layer was performed using 19 kg (solid content: 5.7 kg) to obtain a sustained-release preparation of the present invention.
- the dissolution test was performed according to the Japanese Pharmacopoeia paddle method at 100 rpm. As the eluate, buffers of various pHs assuming the inside of the human digestive tract were used. The results are shown in Figure 3. The dissolution test was also performed for 2 months with (1) 60 ° C heating test, (2) humidification test at 40 ° C 75%, and (3) light exposure test. And examined its stability. Purified water was used for the eluate. Figure 4 shows the results. In the figure, “initial” refers to the drug product without any treatment. In the dissolution test using the paddle method of the Japanese Pharmacopoeia, a similar release pattern was observed at any pH, and no change in the pattern due to pH was observed.
- Fluid bed granulation by mixing this compound (the drug substance; 30 g) with mannitol (577 g), microcrystalline cellulose (300 g), low-substituted hydroxypropylcellulose (50 g), and light anhydrous silicic acid (5 g) Hydroxypropylcellulose (30 g) aqueous solution was sprayed with a machine to granulate. After the completion of granulation, the mixture was dried, mixed with magnesium stearate (8 g), and compressed into tablets to obtain uncoated tablets. Hydroxypropyl methylcellulose (9 g), macrogol 6000 (0.9 g), titanium oxide (3 g) and water were added to the obtained uncoated tablets, and a coating solution was prepared so that the total amount became 90 g. The resulting uncoated tablets were coated to give tablets (10000 tablets) containing 3 mg of the present compound.
- This compound (the drug substance; 30 g), corn starch (187.5 g) and light anhydrous silicic acid (lg) were mixed. This was coated and granulated by using a solution of hydroxypropylcellulose (24 g) in ethanol (376 g) as a binder and microcrystalline cellulose particles (700 g) as core particles. The granules were dried using a fluid bed dryer Later, it was classified.
- the obtained drug particles (400 g) were combined with glycerin fatty acid ethyl (15.6 g), hydroxypropylmethylcellulose (TC5EW: registered trademark, manufactured by Shin-Etsu Chemical Co., Ltd.) (1.6 g) and ethylcellulose (Aquacoat) (Registered trademark, Asahi Kasei Corporation) (109.2 g, 62.8 g as solid content). After applying the prescribed coating solution, curing was performed. The obtained granules were filled into gelatin capsules so that the content of the present compound per 1 capsule was 3 mg.
- Example 1 the dissolution test was performed according to the Japanese Pharmacopoeia paddle method 100 rpm. A stability test was performed in the same manner as in Example 1. Purified water was used as the eluate. However, the light exposure was performed using a 300k look instead of a 1200k look. The results are shown in Figure 6 (Paddle method dissolution test in the Japanese Pharmacopoeia) and Figure 7 (Stability test). As a result of the dissolution test, no difference in dissolution due to pH was observed. After accelerated heating, humidification, and light exposure tests (stability tests), light brown discoloration was observed with the naked eye under all conditions. As shown in FIG. 7, among the accelerated tests, the dissolution rate of the formulation after the 60 ° C. heating test was significantly increased, and a change with time was observed. Comparative Example 3: Sustained-release preparation using Eudragit RS30D (registered trademark)
- This compound (the drug substance; 30 g), corn starch (187.5 g), and light anhydrous silicic acid (lg) were mixed. This was coated and granulated by using a solution of hydroxypropyl cellulose (24 g) in ethanol (376 g) as a binder and microcrystalline cellulose particles (700 g) as core material particles. The granulated product was dried using a fluidized bed drier and then classified.
- the obtained drug particles (400 g) were added to talc (16.2 g) and triester citrate.
- curing was performed at the end of the application of the predetermined coating solution.
- the obtained granules were filled into gelatin capsules so that the content of the present compound per capsule was 3 mg.
- Fig. 8 shows the results. A large difference was observed in the elution rate depending on the pH. Elution was very slow at pH 1.2 and pH 6.8, and elution was fast at pH 4.0, indicating that stable release was not obtained when administered to humans. Eudragit R S is not considered to be affected by pH, but it can be seen that the formulation of the present compound is.
- Table 1 summarizes the results of Example 1 and Comparative Examples 1 to 3.
- the sustained-release preparation of the present invention shows an appropriate release pattern, has no change in the release pattern due to pH, and shows no coloring during storage, and is an excellent preparation.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/399,686 US7041317B2 (en) | 2000-10-23 | 2001-10-22 | Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2[2-[4-(2-methoxyphenyl) piperazinyl]ethylamino] pyrimidine trihydrochloride as active ingredient |
EP01978845A EP1334723A4 (en) | 2000-10-23 | 2001-10-22 | PROLONGED RELEASE PREPARATION CONTAINING 5-ACETYL-4,6-DIMETHYL-2- (2- (4- (2-METHOXYPHENYL) PIPERAZINYL) ETHYLAMINO) PYRIMIDINE TRIHYDROCHLORIDE AS THE ACTIVE INGREDIENT |
AU2002210915A AU2002210915A1 (en) | 2000-10-23 | 2001-10-22 | Sustained-release preparation containing 5-acetyl-4,6-dimethyl-2-(2-(4-(2-methoxyphenyl)piperazinyl) ethylamino)pyrimidine trihydrochloride as active ingredient |
JP2002537319A JPWO2002034268A1 (ja) | 2000-10-23 | 2001-10-22 | 5−アセチル−4,6−ジメチル−2−[2−[4−(2−メトキシフェニル)ピペラジニル]エチルアミノ]ピリミジン・三塩酸塩を有効成分として含有する徐放性製剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-322825 | 2000-10-23 | ||
JP2000322825 | 2000-10-23 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002034268A1 true WO2002034268A1 (fr) | 2002-05-02 |
Family
ID=18800629
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/009241 WO2002034268A1 (fr) | 2000-10-23 | 2001-10-22 | Preparation a liberation prolongee contenant comme principe actif du trihydrochlorure de 5-acetyl-4,6-dimethyl-2-(2-(4-(2-methoxyphenyl)piperazinyl)ethylamino)pyrimidine |
Country Status (5)
Country | Link |
---|---|
US (1) | US7041317B2 (ja) |
EP (1) | EP1334723A4 (ja) |
JP (1) | JPWO2002034268A1 (ja) |
AU (1) | AU2002210915A1 (ja) |
WO (1) | WO2002034268A1 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10296720B2 (en) | 2005-11-30 | 2019-05-21 | Gearbox Llc | Computational systems and methods related to nutraceuticals |
US8068991B2 (en) * | 2005-11-30 | 2011-11-29 | The Invention Science Fund I, Llc | Systems and methods for transmitting pathogen related information and responding |
US7927787B2 (en) | 2006-06-28 | 2011-04-19 | The Invention Science Fund I, Llc | Methods and systems for analysis of nutraceutical associated components |
US7827042B2 (en) | 2005-11-30 | 2010-11-02 | The Invention Science Fund I, Inc | Methods and systems related to transmission of nutraceutical associated information |
US8297028B2 (en) | 2006-06-14 | 2012-10-30 | The Invention Science Fund I, Llc | Individualized pharmaceutical selection and packaging |
US8340944B2 (en) | 2005-11-30 | 2012-12-25 | The Invention Science Fund I, Llc | Computational and/or control systems and methods related to nutraceutical agent selection and dosing |
US7974856B2 (en) | 2005-11-30 | 2011-07-05 | The Invention Science Fund I, Llc | Computational systems and methods related to nutraceuticals |
US8000981B2 (en) | 2005-11-30 | 2011-08-16 | The Invention Science Fund I, Llc | Methods and systems related to receiving nutraceutical associated information |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007369A1 (en) * | 1987-03-27 | 1988-10-06 | The Wellcome Foundation Limited | Pharmaceutical formulations |
WO1990014077A1 (en) * | 1989-05-22 | 1990-11-29 | Kinaform Technology, Inc. | SUSTAINED RELEASE PHARMACEUTICAL PREPARATIONS HAVING pH CONTROLLED MEMBRANE COATINGS |
US5075308A (en) * | 1989-08-31 | 1991-12-24 | Hitachi Chemical Co., Ltd. | Method for treating urinary obstruction |
JPH0873345A (ja) * | 1994-09-05 | 1996-03-19 | Terumo Corp | 医薬製剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0696561B2 (ja) * | 1985-08-30 | 1994-11-30 | 正幸 石川 | 新規な2−(4−フエニル−1−ピペラジニルアルキル)アミノピリミジン誘導体及びその酸付加塩 |
-
2001
- 2001-10-22 WO PCT/JP2001/009241 patent/WO2002034268A1/ja not_active Application Discontinuation
- 2001-10-22 JP JP2002537319A patent/JPWO2002034268A1/ja active Pending
- 2001-10-22 US US10/399,686 patent/US7041317B2/en not_active Expired - Fee Related
- 2001-10-22 AU AU2002210915A patent/AU2002210915A1/en not_active Abandoned
- 2001-10-22 EP EP01978845A patent/EP1334723A4/en not_active Withdrawn
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1988007369A1 (en) * | 1987-03-27 | 1988-10-06 | The Wellcome Foundation Limited | Pharmaceutical formulations |
WO1990014077A1 (en) * | 1989-05-22 | 1990-11-29 | Kinaform Technology, Inc. | SUSTAINED RELEASE PHARMACEUTICAL PREPARATIONS HAVING pH CONTROLLED MEMBRANE COATINGS |
US5075308A (en) * | 1989-08-31 | 1991-12-24 | Hitachi Chemical Co., Ltd. | Method for treating urinary obstruction |
JPH0873345A (ja) * | 1994-09-05 | 1996-03-19 | Terumo Corp | 医薬製剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1334723A4 * |
Also Published As
Publication number | Publication date |
---|---|
EP1334723A4 (en) | 2005-08-31 |
US7041317B2 (en) | 2006-05-09 |
AU2002210915A1 (en) | 2002-05-06 |
JPWO2002034268A1 (ja) | 2004-03-04 |
EP1334723A1 (en) | 2003-08-13 |
US20050101606A1 (en) | 2005-05-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU760006B2 (en) | Method for making granules with masked taste and instant release of the active particle | |
EP1940361B1 (en) | Pharmaceutical dosage forms having immediate release and/or controlled release properties | |
AU781707B2 (en) | Oral pharmaceutical forms of administration with a delayed action | |
KR100535954B1 (ko) | 장용 피복된 약학 정제 및 이의 제조방법 | |
US20090324717A1 (en) | Extended release pharmaceutical formulation of metoprolol and process for its preparation | |
CS244909B2 (en) | Production method of retarded form of bromohexine | |
PT1615622E (pt) | Formulações de doxiciclinas de dose única diária | |
JP6148252B2 (ja) | 新規配合剤 | |
CN101977593A (zh) | 包含弱碱性药物以及有机酸的给药系统 | |
WO2006128070A2 (en) | Pharmaceutical dosage forms having immediate release and/or controlled release properties that contain a gabab receptor agonist | |
US20030224045A1 (en) | Combination immediate release sustained release levodopa/carbidopa dosage forms | |
PL192950B1 (pl) | Wielocząstkowa postać farmaceutyczna o opóźnionym i stopniowym uwalnianiu, oraz sposób jej wytwarzania | |
WO2002034268A1 (fr) | Preparation a liberation prolongee contenant comme principe actif du trihydrochlorure de 5-acetyl-4,6-dimethyl-2-(2-(4-(2-methoxyphenyl)piperazinyl)ethylamino)pyrimidine | |
JP2001522794A (ja) | カルベジロールの新規経口剤形 | |
JP2009519313A (ja) | 医薬組成物 | |
EP1178780A1 (en) | Multiparticulate controlled release selective serotonin reuptake inhibitor formulations | |
JPH04234812A (ja) | 持続性製剤用顆粒 | |
WO2005097079A2 (en) | Controlled release dosage for gaba receptor agonist | |
JPWO2004066991A1 (ja) | タムスロシンまたはその塩の腸溶性徐放微粒子およびその製造法 | |
CN114340601A (zh) | 掩盖了令人不快的味道的颗粒剂及其制造方法 | |
WO2005051362A2 (en) | Oral benzimidazole compositions comprising an active core, an optional separating layer and an enteric coating | |
KR20050016449A (ko) | 레보도파/카르비도파의 즉시 방출 및 제어 방출 조합 투여형 | |
WO2005016317A1 (en) | Process for manufacture of extended release pellets containing diltiazem hci | |
NZ718686A (en) | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof | |
JPH05163163A (ja) | 有核製剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002537319 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10399686 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001978845 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001978845 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001978845 Country of ref document: EP |